OncoMed’s bad, no good, disastrous month continues as another PhII flops, PhIb trial is shuttered
A few days ago, shares of OncoMed $OMED were blitzed by the news that its top drug demcizumab had flopped in a Phase II study, following it up with the news that Bayer bypassed a tie-up on two other key programs. This morning the biotech added that its drug tarextumab plus chemo also failed a Phase II study. And investigators decided to drop a Phase Ib trial of brontictuzumab after they determined that the drug regimen was not tolerated by patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.